If you follow my blog you have to know that I strongly believe that the "targeted" approach in drug development is pseudo-scientific and very often we can see the failures of targeted drugs. A fresh example:
Bristol-Myers Squibb Co. (BMY) said a Phase 3 trial of its drug, brivanib, as a first-line treatment in patients with liver cancer didn't meet its primary survival objective
No comments:
Post a Comment